| pubmed-article:833750 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:833750 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:833750 | lifeskim:mentions | umls-concept:C1280551 | lld:lifeskim |
| pubmed-article:833750 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:833750 | lifeskim:mentions | umls-concept:C0221102 | lld:lifeskim |
| pubmed-article:833750 | lifeskim:mentions | umls-concept:C0000854 | lld:lifeskim |
| pubmed-article:833750 | lifeskim:mentions | umls-concept:C0036075 | lld:lifeskim |
| pubmed-article:833750 | lifeskim:mentions | umls-concept:C1704711 | lld:lifeskim |
| pubmed-article:833750 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:833750 | pubmed:dateCreated | 1977-3-31 | lld:pubmed |
| pubmed-article:833750 | pubmed:abstractText | Meglumine labeled with carbon-14 was administered orally as 14C-meglumine salicylate to rats and dogs to study its distribution and excretion. The compound was incompletely absorbed; that which was absorbed was rapidly excreted in the urine. Peak blood levels were about 5-10 mug/ml in rats and 2-8 mug/ml in dogs. Tissue levels were negligible at the end of the experimental periods. No evidence for N-demethylation or oxidation to carbon dioxide was obtained. | lld:pubmed |
| pubmed-article:833750 | pubmed:language | eng | lld:pubmed |
| pubmed-article:833750 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:833750 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:833750 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:833750 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:833750 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:833750 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:833750 | pubmed:issn | 0022-3549 | lld:pubmed |
| pubmed-article:833750 | pubmed:author | pubmed-author:KesslerW VWV | lld:pubmed |
| pubmed-article:833750 | pubmed:author | pubmed-author:ShawS MSM | lld:pubmed |
| pubmed-article:833750 | pubmed:author | pubmed-author:BornG SGS | lld:pubmed |
| pubmed-article:833750 | pubmed:author | pubmed-author:LangeW EWE | lld:pubmed |
| pubmed-article:833750 | pubmed:author | pubmed-author:HeegJ FJF | lld:pubmed |
| pubmed-article:833750 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:833750 | pubmed:volume | 66 | lld:pubmed |
| pubmed-article:833750 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:833750 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:833750 | pubmed:pagination | 96-9 | lld:pubmed |
| pubmed-article:833750 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:833750 | pubmed:meshHeading | pubmed-meshheading:833750-A... | lld:pubmed |
| pubmed-article:833750 | pubmed:meshHeading | pubmed-meshheading:833750-S... | lld:pubmed |
| pubmed-article:833750 | pubmed:meshHeading | pubmed-meshheading:833750-F... | lld:pubmed |
| pubmed-article:833750 | pubmed:meshHeading | pubmed-meshheading:833750-R... | lld:pubmed |
| pubmed-article:833750 | pubmed:meshHeading | pubmed-meshheading:833750-B... | lld:pubmed |
| pubmed-article:833750 | pubmed:meshHeading | pubmed-meshheading:833750-D... | lld:pubmed |
| pubmed-article:833750 | pubmed:meshHeading | pubmed-meshheading:833750-M... | lld:pubmed |
| pubmed-article:833750 | pubmed:meshHeading | pubmed-meshheading:833750-M... | lld:pubmed |
| pubmed-article:833750 | pubmed:meshHeading | pubmed-meshheading:833750-T... | lld:pubmed |
| pubmed-article:833750 | pubmed:meshHeading | pubmed-meshheading:833750-I... | lld:pubmed |
| pubmed-article:833750 | pubmed:year | 1977 | lld:pubmed |
| pubmed-article:833750 | pubmed:articleTitle | Absorption, distribution, and excretion of 14C-meglumine in rats and dogs after administration of 14C-meglumine salicylate. | lld:pubmed |
| pubmed-article:833750 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:833750 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
